System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Roger E G Schutgens is an expert in Hematology at University Medical Center Utrecht (Netherlands). As of October 2026, ScienceLeadR ranks Roger E G Schutgens in the top 1% of experts worldwide for Hemophilia A, Blood Platelet Disorders and Embolism and Thrombosis. Roger E G Schutgens has authored 369 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 3 of them ongoing. SLR score: 1,105 (community average: 125). How the SLR is computed.

LeadR Profile

Roger E G Schutgens University Medical Center Utrecht Netherlands
1 105 ScienceLeadR Reputation 1105

Unlock

Register Login
Network Map

Hematology

Subspecialties: Genetics - Pharmacy - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026
Source: PubMed

University Medical Center Utrecht

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 369

Citations

Citations: 12 248 1st author: 23 Last author: 54 Unique author: 12

Main journals

Haemophilia 67
J Thromb Haemost 43
Blood 33
Res Pract Thromb Haemost 30
Hemasphere 24

Best Journals

JAMA 6
N Engl J Med 4
Lancet Haematol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Perioperative von Willebrand Factor and Factor VIII Kinetics in von Willebrand Disease Patients Treated With Different Clotting Factor Concentrates.
PMID 42670766 — thromboembolism, factor viii, von willebrand diseases, von willebrand factor, perioperative care, hemophilia a, blood coagulation factors, pharmacokinetics		Haemophilia20260
A multicenter prospective observational cohort study to improve diagnostic yield and clinical management of persons with a Bleeding Disorder of Unknown Cause (BDUC-iN study protocol).
PMID 42662916 — quality of life, hemorrhage, hemostatics, cohort studies, blood coagulation disorders, research, therapeutics, hemostasis, prospective studies		Res Pract Thromb Haemost20260
Long-term prosthesis survival of total hip and total knee arthroplasty in people with inherited bleeding disorders.
PMID 42633224 — arthroplasty, joint diseases, hemorrhage, hemophilia a, arthroplasty, replacement, knee, arthroplasty, replacement, survival rate		Res Pract Thromb Haemost20260
Responsiveness and Minimal Important Change of the Haemophilia Activities List in Patients With Inherited Bleeding Disorders.
PMID 42219951 — activities of daily living, hemorrhage, pain, hemophilia a, research		Haemophilia20260
Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).
PMID 42101205 — ivermectin, probability, covid-19, pneumonia, critical illness, intensive care units, antiviral agents, community-acquired pneumonia		Crit Care Med20260

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 3
Phase 3 3
Phase 1/Phase 2 1
Phase 2 1
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 4
Active not recruiting 2
Recruiting 2
Unknown 2

By type:

Interventional 8
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 3
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Pharmacokinetic guided Dosing of Emicizumab
NCT06320626 — hemorrhage, antibodies, adolescent, hemophilia a, antibodies, monoclonal, drug tapering, antibodies, bispecific, child		Phase 4Recruiting2022
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219 — cells, safety, b-cell activating factor, double-blind method, tablets, b-cell activation factor receptor, solutions, therapeutics, steroids, purpura, thrombocytopenic, purpura, receptors, interleukin-4, b-lymphocytes, thrombocytopenia, purpura, thrombocytopenic, idiopathic		Phase 3Active not recruiting2023
A Study Evaluating the Efficacy and Safety of Mitapivat (AG 348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780 — cells, safety, anemia, sickle cell, anemia, tablets		Phase 2/Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS